Technologies and cancer therapies develop at a rapid pace, which makes staying current with changes diffi cult for nurses. Newer cancer modalities combine surgery or interventional radiology techniques to deliver regional chemotherapy, limiting systemic toxicities. Chemotherapy-certifi ed nurses must be available to assist with chemotherapy administration in nontraditional areas. This article provides an overview of how clinical trials were implemented using newer modalities that integrate surgery or interventional radiology to deliver regional chemotherapy in a research setting in a safe, effective manner.
C ombination chemotherapy and surgery traditionally have been primary treatments for several types of cancer, including colorectal carcinoma, hepatocellular carcinoma, and metastatic ocular melanoma. Combining multiple modalities to fi ght cancer is thought to produce better response rates compared to use of a single form of therapy. However, systemic toxicities often limit the amount of chemotherapy that a patient can receive. Regional infusion of chemotherapy allows direct exposure to the neoplasm while limiting systemic toxicities (Alexander, Bartlett, Fraker, & Libutti, 1996; Soulen, 1994; Wallace, 1984) . Infusion of hepatic intra-arterial chemotherapy has been revisited many times since the 1980s, and intra-arterial chemotherapy as well as other regional chemotherapy regimens have become popular again (Reid & Sze, 2002; Wallace) . For many years, interventional radiologists have been injecting chemotherapy, usually doxorubicin, cisplatin, or mitomycin C, selectively through catheters into the hepatic artery to treat unresectable hepatocellular carcinoma. Administration usually is combined with embolization or blockage of blood vessels (Camma et al., 2002) .
In the authors' institution, clinical trials have been developed to test the effi cacy of regional antineoplastic therapies. The trials, performed in the operating room (OR) and interventional radiology (IR) suite, have produced new challenges and expanded the role of surgical and IR staff delivering antineoplastic therapies. Trials consist of surgery with intraoperative regional This material is protected by U.S. copyright law. Unauthorized reproduction is prohibited. To purchase quantity reprints, please e-mail reprints@ons.org or to request permission to reproduce multiple copies, please e-mail pubpermissions@ons.org. chemotherapy perfusion (melphalan or cisplatin), intra-arterial melphalan percutaneous hepatic perfusion performed in the IR suite, or systemic liposomal doxorubicin (ThermoDox™, Celcion Corporation, Columbia, MD) administration with concomitant radiofrequency ablation (RFA).
Chemotherapy is administered either in the IR suite or the OR, two areas that traditionally do not employ chemotherapy-certifi ed nurses. This practice has lead to the development of creative procedures to safely administer hazardous drugs and maintain the safety of patients and personnel. The protocols are outlined more extensively in the fi rst part of this series (see page 338). Because patients receive general anesthesia for all of the procedures, anesthesiologists are responsible for all drug administration except for chemotherapy.
Rapid technologic advances have caused the literature as well as practitioners to become less current more rapidly. This article will provide an outline for administering chemotherapy in nontraditional settings for oncology and address related nursing practice issues. This article also will discuss the care of patients in the IR suite or the OR as well as postoperatively.
Chemotherapy Administration in Interventional Radiology
The fi rst clinical trial involving the IR suite was with percutaneous hepatic perfusion (PHP). Lessons learned though experience with the PHP study were applied to the ThermoDox plus RFA protocol. Therefore, this section primarily will explain requirements for implementing the PHP protocol. Differences between the implementation of the different protocols will be established as necessary.
Percutaneous Hepatic Perfusion: The Process
The fi rst step was to compare strategies of accommodating chemotherapy administration on nononcology units among several institutions. At the time, the institutions did not have similar treatment protocols in the IR suite or the OR, so the comparison was not insightful. When the Maryland Nurse Practice Act was reviewed to fi nd whether nursing restrictions were in place for administration of intra-arterial chemotherapy, none could be found.
A search of the literature published during the past 10 years yielded no helpful information regarding nursing care of patients with cancer receiving chemotherapy in the IR suite. Information regarding the use of regional chemotherapy was found in articles written within the past 25 years, but again, none addressed nursing issues then or now (Adam, 2002; Arai, 1996; Barth & Matsumoto, 1991; Chisholm, Berman, de Carvalho, & Gorrell, 1993; Minakuchi et al., 1992; Otto, 1995; Reid & Sze, 2002; Rosch, Keller, & Kaufman, 2003; Simonetti, Orlacchio, Fanucci, & Chiusano, 1994; Wallace, 1984; Wallace, Chuang, Zornoza, & Cohen, 1981) .
The Team
Implementation of the protocols discussed in this article was a collaborative, interdisciplinary effort. The PHP protocol set the standard for all chemotherapy protocols involving IR. A clinical nurse specialist (CNS) reviewed the PHP protocol and met with the intensive care unit (ICU) nurse manager. They decided that an ICU chemotherapy-certifi ed nurse would accompany patients to the IR suite and administer chemotherapy because patients spend 24 hours in the ICU postprocedure due to potential side effects from therapy. The ICU nurse also is responsible for adhering to all policies and procedures regarding hazardous drug infusions and those surrounding hazardous spills. The CNS also met with the protocol research nurse, ICU nurses, IR nurses and technicians, and nurses on the surgical oncology unit, where patients are transferred after their stay in the ICU. Together, they divided roles and responsibilities. Then, all of the information was reviewed with physician team members, including surgical oncologists, interventional radiologists, and anesthesiologists. The process truly was multidisciplinary.
The Methods
The decision was made to develop the institution's safe handling guidelines for hazardous drugs based on those from the Oncology Nursing Society (ONS) (Polovich, 2003; Polovich, White, & Kelleher, 2005) and the Occupational Safety and Health Administration (National Institute for Occupational Safety and Health, 2004) . Because all staff in IR were going to be involved in the procedure, staff education was essential. Staff education included direction on the use of personal protective equipment (PPE) for chemotherapy administration, such as a gown, mask, gloves, and goggles. IR nurses' roles include that of scrub nurse assisting the interventional radiologist. Scrub nurses have direct contact with the DelCath catheter (DelCath Systems, Inc., Stamford, CT) through which chemotherapy is infused. The DelCath System Kit uses a series of catheters and fi lters to target drug delivery to the liver and fi lters the drug before it reaches the systemic circulation. Technologists in IR are exposed to the chemotherapy because they are responsible for all of the equipment in the IR suite. During the procedure, everyone in the IR suite is at risk for exposure to chemotherapy because the potential always exists for spillage of chemotherapy or body fl uids.
Collaboratively, oncology-and chemotherapy-certifi ed nurses and IR nurses developed a safe technique for delivering the chemotherapeutic agent. The PHP protocol requires melphalan to be infused at 25 ml per minute into the hepatic arterial tree. Because the rate exceeds the maximum rate of standard IV pumps, the MedRad ® pump (Medrad, Inc., Indianola, PA) that was available in the IR suite was used (see Figure 1) . The MedRad pump is capable of arterial infusions exceeding 10 ml per second and typically is used for contrast during arteriograms. Through testing with saline, a method was developed for delivering melphalan through a closed system, decreasing the risk of spillage or aerosolization of the drug. Technologists usually manage the MedRad pump during angiography. Because technologists are the most experienced at setting the MedRad pump, they do so for chemotherapy infusion, and as per institutional policy, a chemotherapy-certifi ed nurse double-checks all calculations and settings. A core group of IR nurses are becoming chemotherapy and biotherapy certifi ed to establish a backup system. When another chemotherapycertifi ed nurse in IR is not available, a chemotherapy nurse from the surgical oncology unit assists the ICU nurse with independent double checks. The procedures are detailed in 
Chemotherapy Administration in the Operating Room
The challenge of administering chemotherapy in a nontraditional setting also is present in the OR at the authors' institution. Two protocols involve regional melphalan administered via a 60-minute isolated hepatic perfusion (IHP) for patients with limited unresectable liver disease. Two other protocols entail cytoreductive surgery for patients with peritoneal carcinomatosis followed by intraoperative continuous hyperthermic peritoneal perfusion (CHPP) with cisplatin with or without postoperative interperitoneal paclitaxel and 5-fl uorouracil. Interperitoneal chemotherapy is given on the surgical oncology unit 7-12 days postoperatively.
Preparation for Patient Care
An OR nurse visits a patient on the nursing unit the day before surgery, reviews his or her medical record for previous cancer therapies and concomitant morbidities, performs a physical assessment, and educates him or her on the plan for the next day's surgery. In addition to routine procedures for major surgeries, the OR nurse reviews the chemotherapy administration the patient will receive intraoperatively. The teaching is reinforced by nurses on the surgical oncology unit. Depending on the protocol, the patient will either receive intra-arterial melphalan via IHP or heated cisplatin as a peritoneal wash as part of the CHPP protocol. Protocol-specifi c requirements in the OR during CHPP and IHP are outlined in Table 3 and Table 4 , respectively. The specifi c surgeries are explained in detail in the fi rst part of this series.
Day of Surgery
Once a patient has been prepped and given appropriate surgical interventions, the OR nurse checks the chemotherapy dose when the drug arrives in OR. The dosage is double-checked by the provider administering chemotherapy (the perfusionist for IHP or the surgeon for CHPP). With IHP, the perfusionist handles the chemotherapy because melphalan must be administered through the Cobe Perfusion System (Cobe, Lakewood, CO) (see Figure 2 ). The perfusion pump is similar to ones used in coronary bypass surgery, and perfusionists receive special training to run the machine. Because their technical skills are required for the perfusion, perfusionists are taught safe handling of hazardous drugs and wear appropriate PPE.
The person administering chemotherapy also disposes of the chemotherapy-containing bag postperfusion into appropriate chemotherapy disposal containers, which already are placed in medical product waste boxes to limit further contact. Disposal must be done with care and caution to limit potential staff contact with hazardous material. If not disposed of according to procedure, the waste must be repacked by the OR circulator in an acceptable manner, which could cause aerosolization and spread of hazardous substances. Patients are transferred to the ICU postoperatively for one to two days observation because the surgical procedures are extensive.
Patient Care: Pre-, Intra-, and Postprocedure
The role of ICU nurses in regard to the PHP and ThermoDox plus RFA protocols is multifaceted. An ICU nurse provides continuity of care from the time a patient is on the table in the IR suite until his or her discharge from the ICU, when a surgical oncology nurse assumes patient care. ICU and surgical oncology nurses must have a clear understanding of the protocols. On the day of treatment, an ICU nurse obtains the chemotherapy after preparation by the pharmacy and proceeds to the IR suite to administer the infusion.
The ICU nurse dons the proper chemotherapy PPE and ensures that all members of the team who will handle the chemotherapy or body fl uids intra-and postinfusion are wearing the same required gear. He or she ensures that the chemotherapy is checked against the physician's order, that tubing is primed as soon as it arrives from the pharmacy, and that the rate and volume set on the MedRad or IV pump are correct. Because of the drug's short stability, melphalan must be administered within one hour of preparation per protocol guidelines. The ICU nurse and research nurse serve as the timekeepers during the respective procedures to ensure chemotherapy is administered and serial blood draws are timed according to protocol guidelines.
According to PHP protocol, once the melphalan infusion has completed within a 30-minute time frame, the IR nurse and The IR team places a sheath in the patient's right femoral artery for an arteriogram.
The IR team embolizes vessels as necessary. The DelCath perfusion system is opened by an IR team member on the radiologist's request. The right femoral vein is accessed by the radiologist, and the perfusion catheter is placed.
Chemotherapy Setup
Melphalan is ordered by the principal investigator (PI) or associate investigator (AI). The pharmacy does not make the drug until requested by the interventional radiologist or surgeon. After melphalan is ordered, the dose is calculated and verifi ed by two chemotherapy-certifi ed nurses. When melphalan arrives in IR, two chemotherapy-certifi ed nurses do independent double-checks of the patient's name and the drug volume, dose, and rate of administration. Prior to loading the MedRad ® pump with melphalan, personal protective equipment (PPE) is donned and spill pads are placed on the fl oor under the MedRad machine.
Loading the MedRad Pump
A nurse primes the secondary tubing with 0.9% sodium chloride. Under the direction of the PI or AI, the IR nurse sets up the arterial melphalan infusion system. A chemotherapy-certifi ed nurse spikes the melphalan using nonvented secondary tubing. The IR nurse ensures that the roller clamp is closed except when loading melphalan into the MedRad syringe. The three-way stopcock is attached to the MedRad pump. The straight end is attached to sterile pressure tubing. The nonvented secondary tubing is attached to the sidearm of the three-way stopcock. The IR nurse ensures that the distal three-way stopcock on the MedRad syringe is turned off to the patient's arterial catheter. One or two three-way stopcocks and 10 ml syringes are attached to the proximal end of the pressure tubing by the radiologist. Under supervision of the PI or senior staff designee and chemotherapy nurse, the IR nurse loads melphalan into the MedRad syringe. The IR nurse and radiologist ensure that all chemotherapy tubing connections are secure. The radiologist places the proximal three-way stopcocks and 10 ml syringes into a sterile plastic bag containing a sterile towel and gauze. The distal three-way stopcock is turned off to the melphalan bag and opened to the patient. Using the manual wheel at the end of the MedRad pump, the pressure tubing is primed. The radiologist removes air from the system via the 10 ml syringe. Under supervision of the chemotherapy nurse and the PI or AI, the IR technologist programs the pump at the prescribed rate.
The melphalan infusion rate and volume are double-checked by the chemotherapy nurse and the AI or PI prior to infusion.
Ensures correct patient and procedure as well as appropriate documentation -
The left jugular IV is used for access during and after the procedure. The right jugular access is for the DelCath perfusion return system. The return system has a large-bore, three-way stopcock attached to the distal end. Sterile extension tubing leads to a heparinized IV pump infusing at 50 ml per hour. The arteriogram maps the patient's vessels to determine the need for embolization. The arterial line may be attached to pressure extension tubing and used to monitor blood pressure. Prevents chemotherapy from leaking into the intravascular system Prevents waste of expensive equipment -Melphalan needs to be infused within 60 minutes of reconstitution.
Multiple checks ensure correct rate, volume, and dosage.
Safety checks to avoid errors
The MedRad pump is a rapid infuser pump used to give bolus-dose IV contrast at rates in excess of 10 ml per second. Protective gear provides staff protection in case of a chemotherapy spill.
Per institution policy guidelines
Decreases risk of a chemotherapy spill Connects melphalan to the MedRad syringe for infusion Enables melphalan to be loaded into the MedRad using a closed system Allows melphalan to be loaded into the syringe and prevents the backfl ow of blood or air embolus Reduces risk of chemotherapy spill and air embolus; the radiologist determines the number of stopcocks and syringes needed. Air bubbles should be avoided when loading the syringe to reduce the risk of air embolus. Decreases risk of spill; melphalan is infused at a high rate of 25 ml per minute via the MedRad pump. Air from the pressure tubing is purged into a syringe and decreases the risk of contamination of the sterile fi eld with the chemotherapeutic agent. Prevents melphalan from being injected back into the bag Prevents the priming system from running or infusing at a rapid rate Example: 500 ml total volume infuses over 20-25 minutes. The rate is 25-30 ml per minute. The dose is divided into three infusions because the syringe size is 200 ml. The time needed to refi ll the MedRad syringe is accounted for when setting the rate. Ensures correct MedRad pump setting radiologist disconnect the infusion tubing from the DelCath system. The tubing is disposed of in the proper chemotherapy waste containers. According to the ThermoDox plus RFA protocol, a chemotherapy-certifi ed nurse is responsible for the entire infusion of ThermoDox because it is administered via IV. The chemotherapy nurse assesses the infusion site for an adequate blood return and performs all safety routines, including dose double-checks, IV pump double-checks, PPE gear, and availability of a spill kit. Once IV pump settings have been double-checked and chemotherapy is initiated, the ICU nurse monitors the infusion and infusion site, responds as needed to any complications (including acute side effects, infi ltrations or extravasations, or chemotherapy spills), and communicates any concerns with the interventional radiologist. Communication is crucial because the RFA commences 15 minutes into the 30-minute infusion of ThermoDox. The nurse also is responsible for disposing of the empty drug bag and tubing.
Percutaneous Hepatic Perfusion: Postprocedure Patient Care
Following PHP, patients are returned to the ICU for an overnight stay. They are extubated per anesthesia, dressings are applied to all puncture sites by the IR nurse, and the DelCath sheaths are securely dressed for transport.
Once patients arrive in the ICU, postprocedure laboratory draws are obtained and electrolytes are replaced when indicated. Protamine sulfate is given to reverse heparin-associated coagulopathy. Heparin is a necessary part of the perfusion to prevent blood clotting caused in the fi lter in the DelCath system. The typical dose of protamine is 25-50 mg administered via IV and diluted in 25 ml 0.9% sodium chloride or dextrose 5% in water over a minimum of 10 minutes. Protamine administration requires close patient monitoring for signs or symptoms of hypersensitivity reaction, which may be immediate or delayed and include hypotension, fl ushing, nausea, vomiting, dyspnea, bradycardia, and anaphylactoid reactions (e.g., circulatory collapse, capillary leak, noncardiogenic pulmonary edema) (Sweetman, 2005) .
Because the catheters are inserted into the femoral artery and vein, a nurse must monitor the groin and internal jugular puncture sites and distal pulses frequently for bleeding or loss of pulse. Patients are instructed to inform a nurse if they develop a sudden increase in pain or change in sensation in the affected leg, which could be caused by ischemia. Patient teaching includes the need for frequent pulse and puncture site checks as well as the need to 
Chemotherapy Infusion
At the direction of the PI or AI and interventional radiologist, the perfusionist engages the bypass fi ltration system.
At the direction of the PI or AI and radiologist, the technologist activates the MedRad pump. The IR nurse continuously monitors tubing for any sign of leakage or air.
Reloading the MedRad Syringe Pump
The IR nurse ensures the proximal and distal three-way stopcocks are closed to the patient and open to the MedRad pump. The roller clamp on the secondary tubing is opened. The previously described MedRad loading procedure is followed.
Postperfusion: Final Steps
When the drug infusion is complete, the arterial catheter is removed by the radiologist and placed into the sterile plastic bag with the melphalan infusion tubing and syringes. The contaminated arterial catheter, MedRad syringe, and melphalan tubing are placed in a chemotherapy bucket for disposal. After the 30-minute fi ltration, the PI or AI coordinates fi ltration system removal with the interventional radiologist and the perfusionist. The contaminated perfusion equipment and PPE are placed in a chemotherapy bucket for disposal. The femoral lines and jugular lines are dressed using a sterile technique by the IR nurse. The patient is transferred to the intensive care unit with catheters intact.
The patient's vital signs are taken every 15 minutes including pulse and site checks for one hour, then every 30 minutes for two hours, and then hourly. The patient is reminded to keep his or her legs straight. The patient is given nothing by mouth until he or she is stabilized and catheters are removed.
Ensures correct patient, procedure, and allergy assessment Starting 48 hours before treatment, the patient receives dexamethasone and ranitidine every 12 hours for four doses to prevent allergic reactions. The final premedications are due 30 minutes prior to the start of the ThermoDox™ infusion.
ThermoDox is produced by encapsulating doxorubicin in a heat-activated liposome, which cracks at a temperature of 41°C-42°C (National Institutes of Health, Pharmaceutical Development Section, Clinical Center Pharmacy, 2005). The cooling blankets are turned on to maintain normal body temperature and prevent a systemic release of ThermoDox. The leg-cooling blankets prevent warming of the skin under the grounding pads. --Separate IVs are used for infusion and blood draws to prevent inaccurate pharmacokinetic results. -ThermoDox is heat activated.
Cooling blankets are turned on per radiologists' orders to prevent the patient from overheating and causing systemic release of the chemotherapy.
Decreases risk of infection
When the probe is near the targeted lesion, the radiologist notifi es anesthesia to give the premedications.
Per institution policy
To absorb potential leakage -Per institution policy to decrease the risk of error Ensures correct rate and dose; the infusion dose and rate are determined by the protocol requirements. The timing of the chemotherapy infusion is critical for maximum therapeutic results. Per protocol requirements to optimize chemotherapeutic and heat effect on tumor The grounding pad cooling blankets need to be turned on 15 minutes before RFA administration to prevent heating of the patient's skin under the pads. Heat buildup must be avoided to prevent ThermoDox from being released systemically.
The ICU or research nurse draws blood through the labeled central line. Pharmacokinetic drug levels may be skewed by drawing via the same line the drug is infused through.
-
Preprocedure
The interventional radiology (IR) team verifi es patient allergy assessment and completes a surgical or invasive procedure verifi cation checklist. The IR nurse verifi es that the patient received premedications prior to admission to the hospital and on the surgical oncology unit. The IR nurse ensures that IV dexamethasone, diphenhydramine, and ranitidine premedications that will be needed during the procedure are available for the anesthesiologist to administer.
Patient Preparation
The IR staff place the whole-body cooling blanket on the computed tomography scan table under the patient.
A smaller cooling blanket and skin temperature probes are placed on the legs over the grounding pads. Adhesive temperature discs are placed under the grounding pads to monitor skin temperature via the cooling blanket. The anesthesia team administers anesthesia and monitors the patient. Separate peripheral or central line IVs are started as needed for melphalan infusion and pharmacokinetic blood draws. The drug is administered by the intensive care unit (ICU) chemotherapy-certifi ed nurse after verifying adequate blood return. The IR nurse places the Criticore ® system foley catheter for continuous temperature monitoring using sterile technique. Urine output is monitored by the IR or ICU nurse. The patient's temperature is monitored continuously by the anesthesiologist.
The interventional radiologist is notifi ed if the patient's temperature is 38°C or higher. The IR team prepares the patient for the procedure using standard techniques, including skin preparation and sterile draping. The interventional radiologist places the radiofrequency ablation (RFA) probe near the targeted lesion.
Chemotherapy Setup
The chemotherapy-certifi ed nurse primes IV piggyback tubing with 0.9% sodium chloride and ensures that IV connections are secure. The IR or ICU nurse places a plastic-backed absorbent pad under the IV system.
Chemotherapy Infusion
Chemotherapy is ordered by the principal or associate investigator. The dose is calculated and verifi ed by two chemotherapy-certifi ed nurses. The infusion dose and rate are double-checked by the chemotherapy nurse and principal or associate investigator. Chemotherapy is given at the direction of the interventional radiologist by the chemotherapy-certifi ed nurse. RFA begins 15 minutes after the chemotherapy infusion is initiated.
Grounding pad cooling blankets are turned on when chemotherapy is started.
The IR nurse monitors the temperature under the grounding pads.
Pharmacokinetic Blood Draws
Pharmacokinetics are drawn per protocol requirements by the research or ICU nurse.
End of Procedure
The RFA probe is removed by the interventional radiologist, and a dry, sterile dressing is placed over the site. 
(Continued on next page)
keep the leg straight for eight hours following sheath removal by a physician. The physician applies direct pressure to the catheter femoral insertion site to obtain hemostasis, which may take as long as 30 minutes to achieve. One of the goals during PHP is to occlude the gastroduodenal artery to isolate chemotherapy in the liver. However, patients' blood supply can be variable and potentially lead to incomplete arterial embolization, allowing leakage or backfl ow of chemotherapy to the upper gastrointestinal vasculature if no embolization is performed to isolate the liver blood supply. Embolization of the gastroduodenal artery or any accessory or small replaced hepatic arteries allows for more selective delivery of the drug and less risk of backfl ow into unwanted, nontargeted vascular distributions such as the gastrointestinal tract or duodenum. Patients are monitored by a nurse postperfusion for potential complications such as cholecystitis, gastritis, and duodenitis (B.J. Wood, personal communication, August 18, 2005) .
A baseline pain assessment is made by an ICU nurse, and patients are medicated as needed per physicians' orders. Typically, pain medication is required only prior to or while pressure is being applied to the femoral site during sheath removal. After eight hours have elapsed without complications, a patients is free to advance his or her activity. Before patients are transferred the next day, an ICU nurse reviews their status and any complications or acute side effects from the procedure with a surgical oncology nurse.
ThermoDox Plus Radiofrequency Ablation: Postprocedure Patient Care
According to the ThermoDox plus RFA protocol, patients receive liposomal doxorubicin (ThermoDox) in the IR suite. Fifteen minutes after the infusion begins, an interventional radiologist starts the RFA procedure in the liver. Heat from the RFA probe causes cracks in the liposome capsule, which then leaks doxorubicin and allows regional exposure of chemotherapy to liver lesions while potentially limiting systemic toxicities.
A chemotherapy-certified nurse stays with the patient throughout the procedure and administers the ThermoDox. On arrival in the ICU or postanesthesia care unit, the patient is placed on a cooling blanket, which is turned on if his or her temperature reaches or exceeds 38ºC. Patients' temperatures are monitored continuously for a minimum of six hours via a Criticore ® system temperature-sensing foley catheter (Bard Medical Division, Covington, GA). The rationale is to keep the core body temperature below 38ºC because higher temperatures may break the liposome capsule surrounding the doxorubicin, potentially causing greater systemic release and toxicities. If the cooling blanket is turned on, a patient's skin is covered in lotion and skin integrity is assessed hourly. A sheet is placed between the patient and cooling blanket to help prevent skin breakdown (Perry & Potter, 2003) . Because this is a phase I protocol, frequent blood and urine pharmacokinetics are obtained. One goal of this clinical trial is to determine the biologic half-life of ThermoDox to ascertain how long and at what amount the drug stays in a patient's circulation. Other laboratory work includes complete blood count, liver function tests, chemistries, and coagulation tests immediately postprocedure and then daily until discharge. Strict intakes and outputs are monitored, vital signs are taken frequently, and patients are monitored for any side effects they may experience. Side effects from ThermoDox are being determined during this clinical trial. Patients are assessed for doxorubicinrelated side effects such as nausea, vomiting, mucositis, and myelosuppression (Sweetman, 2005) .
Local pain at the RFA insertion site is not uncommon. If the lesion is at the liver dome, patients also may complain of shoulder pain. An initial pain assessment is done and followed by routine pain assessment; pain medication is administered per physicians' orders.
Isolated Hepatic Perfusion: Postprocedure Care
An OR nurse reports to the ICU nurse before a patient is transferred from the OR. (All postoperative patients going to the ICU are recovered in the ICU in the authors' institution.) An anesthesiologist accompanies patients from the OR and reports on the operative course to the ICU nurse.
The ICU nurse recovers patients from anesthesia, including performing frequent vital signs and physical assessments, medicating for pain, and monitoring for hemodynamic stability. Patients may be hemodynamically unstable immediately following IHP because of extensive intraoperative and postoperative fl uid shifts. Blood products and crystalloids are infused as needed. other injury -Knee-highs are preferred because of the massive fl uid shifts during and after surgery. Skin protection Pink foam is disposable; linen would have to be thrown away, incurring unnecessary cost. Necessary for length of surgery and to monitor urine output closely after cisplatin administration Diaphragm may be compromised, which would require a chest tube.
Betadine must be dry to be effective. Tumor must be able to be debulked to no evidence of disease or 1 cm for intraperitoneal chemotherapy to be effective. -Safety double checks for chemotherapy OR nurses are not chemotherapy certified, so the surgical oncologist handles the chemotherapy. Cisplatin is nephrotoxic (Sweetman, 2005) .
Sodium thiosulfate helps minimize nephrotoxicity (Sweetman, 2005) .
To gauge the intraperitoneal hyperthermia; the surgeon needs to know the exact amount of heat being delivered.
Preoperative
The patient arrives in the operating room (OR) holding area for epidural catheter placement by an anesthesiologist. The patient is interviewed and assessed by the circulating nurse, who also checks for the following information. Intraoperative On arrival in the OR, the patient is positioned on the OR bed with safety straps fastened to the thighs and ankles. The OR nurse prepares the patient for surgery, including doing the following.
Knee-high sequential compression devices are applied before anesthesia induction. Heels placed in heel pads and gel donut Pink foam roll used under knees to prevent back pain
Foley catheter placement
Abdominal shave, including areas for possible chest tube placement Betadine skin preparation from nipple to pubis and across entire lateral surface of skin Once betadine dries, surgical drapes are placed and surgery begins. The surgeon maximally debulks the tumor.
The circulating nurse calls the pharmacy for the cisplatin and sodium thiosulfate after the surgeon confi rms the patient is able to receive the intraperitoneal chemotherapy. The circulating nurse double-checks the chemotherapy with the surgeon who ordered it. The surgeon spikes the chemotherapy onto the tubing for the perfusion.
The anesthesiologist increases hydration in preparation of cisplatin perfusion. IV bolus of sodium thiosulfate is given, followed by a 12-hour infusion.
Urine output is maintained at 200 ml or more per hour. Temperature probes are placed in the left and right abdominal wall and the pelvis to measure temperatures. Generally, patients are extubated immediately postoperatively. Laboratory values are obtained frequently, including complete blood count, chemistries, liver enzymes, and coagulation studies. Liver enzymes may become very high before returning to normal within seven days postoperatively as a result of insult to the liver from the surgery and chemotherapy perfusion.
Patients usually remain in the ICU for two to three days before being transferred to the surgical oncology unit. Communication between nurses from both units is important for continuity of care. An OR nurse also will visit patients on the surgical oncology unit or in the ICU.
Continuous Hyperthermic Peritoneal Perfusion: Postprocedure Patient Care
The postoperative care of a patient undergoing CHPP is somewhat different than with IHP. Because patients receive peritoneal cisplatin during surgery, they return to the ICU with a sodium thiosulfate IV infusion. Sodium thiosulfate helps bind metabolites from the cisplatin, which can cause nephrotoxicity (Sweetman, 2005) . Urine output is maintained at 200 ml per hour for the fi rst 12 hours and then at 100 ml per hour for the next 12 hours postoperatively to prevent acute tubular necrosis. If a patient's urine output is inadequate, diuretics or fl uids are given depending on his or her cardiorespiratory status. Routine ICU patient assessments are performed, and vital signs are monitored frequently. Fluid and electrolyte status as well as blood urea nitrogen and creatinine are monitored carefully because of postoperative fl uid shifts, diuresis, and side effects of cisplatin. ICU and surgical oncology fl oor nurses communicate about patients' OR and ICU stays prior to transfer. Most patients stay in the ICU for one to three days before transfer to the surgical oncology unit.
Nursing and Staff Education
Institutional guidelines mandate that all oncology nurses administering chemotherapy take the institution's class on safe handling and administration of cytotoxic and biologic agents. Nurses complete a test following the class. Once the examination has been passed, a chemotherapy hands-on practicum is required. After practicum completion, nurses are certifi ed to administer hazardous drugs. The guidelines are based on those of the Occupational Safety and Health Administration (National Institute for Occupational Safety and Health, 2004) and ONS (Polovich, 2003; Polovich et al., 2005) . Annual unit-based revalidation of the institution's chemotherapy and biotherapy administration competency ensures continual profi ciency to administer the agents. Protocol-specifi c education also is given in unit-based orientation and on an ongoing basis as needed. OR nurses are not required to take the class because they do not administer hazardous drugs.
Interventional Radiology and Nursing Staff
The combination of IR technology with chemotherapy for cancer therapy makes staff education vital; therefore, education has been a priority in the implementation of protocols. Nursing The patient's abdomen is fi lled with about four liters of 0.9% sodium chloride, and the cisplatin is started on the perfusion circuit. Infl ow and outfl ow catheters are placed in the abdomen and covered with a pool suction tip to facilitate chemotherapy fl ow. The abdomen is closed. The Cobe perfusion pump is set up and run by the surgeon.
An OR technician gently rocks the patient's closed abdomen for 90 minutes.
Temperatures are recorded during this time, including esophageal, right peritoneum, left peritoneum, and pelvis. Once the 90-minute perfusion is completed, the following are done.
The abdomen is opened. Fluid is suctioned out. 
Intraoperative
The patient is placed on the OR table with safety straps fastened to the thighs and ankles.
Knee-high sequential compression devices are applied. The patient is positioned with pink foam roll or pillow under knees and heels in heel pads and gel donuts, and a lower body-warming blanket is applied. Foley catheter is inserted. Abdomen, both axillae, and both groins are shaved. Betadine skin preparation of abdomen, chest, both axillae, genitalia, and bilateral thighs Apply electrocardiogram leads to areas outside of skin preparation. After the patient is draped, the surgeon places a small incision to evaluate for extrahepatic disease. If no extrahepatic disease is found, the surgeon extends the incision and mobilizes the liver. The portahepatic structures are skeletonized. The liver is placed on the extracorporeal perfusion circuit with blood shunted from the liver via venovenous bypass. The nurse calls the pharmacy to start preparing melphalan. The pharmacy provides information regarding the length of time needed to prepare chemotherapy and when the chemotherapy expires. During liver mobilization, the OR nurse ensures that all supplies for chemotherapy administration are available for the perfusionist to administer via the perfusion circuit on the Cobe, including two chemotherapy buckets to dispose of entire perfusion circuit once perfusion is completed. Chemotherapy dose is checked by the OR nurse and again by the perfusionist. At start of melphalan, the OR time clock is set to 60 minutes to perfuse the liver, fl ush the chemotherapy from the liver via the perfusion pump, repair vessels, and achieve hemostatis. A telephone report is called to the intensive care unit (ICU) nurse postperfusion.
Postoperative
Dry sterile dressing is applied. After surgical drapes are removed, a physical assessment is performed to evaluate for any intraoperative injury to skin. The ICU is called with an update of the patient's status and estimated time of arrival to the ICU from the OR. The patient is transferred to the ICU for recovery and ICU care.
•
The patient does not go to an OR holding room because epidural catheters are not inserted because of potential hepatic coagulopathy.
---The left side is the general area where the venovenous bypass pump will be placed. 42ºC is the set temperature for heat-enhanced chemotherapy. To contain any chemotherapy or blood spills Used for intraoperative pump arterial blood gases For melphalan administration via Cobe pump -To set sterile Biomedicus pump To solidify chemotherapy and blood waste products to diminish aerosolization For Cobe pump because it is the circuit for the chemotherapy to be delivered to the liver ---Cost effectiveness
The safety straps on the thighs are standard for any surgery, but the ankle straps give additional protection, preventing the legs from falling off the OR table and risking injury. Promotes venous return Promotes comfort while anesthesia is being induced; warming blanket prevents heat loss and promotes comfort -Required for the venovenous bypass incisions Required for incisions' placement -The procedure is cancelled if extrahepatic disease is present, so the circulating nurse must be near the surgeon to hear the clinical decision. -
The method for isolating and placing the liver so that the chemotherapy is delivered directly to the liver with minimal systemic exposure Cost effectiveness and patient safety are key to this step.
Minimizes or prevents exposure of other staff to hazardous substances Safety double checks -Continuity of care -Ensures quality of care --and IR staff were educated about the protocols via in-service classes and information posted on bulletin boards. An ICU and surgical oncology nurse serve as managers for each protocol, and protocol managers are responsible for ensuring that all nurses have received the education. Protocol managers and a CNS developed a knowledge-and-skills checklist for all ICU nurses who participate in the procedures in the IR suite. A CNS or protocol manager accompanies ICU nurses who are new to the procedure and teaches the protocol to them in the IR suite. Once profi ciency has been ensured, nurses are signed off as able to participate in the procedures independently.
Before the fi rst PHP was performed, a surgical oncology CNS taught in-service classes to IR staff on safe handling of chemotherapy. Basic procedures for safe handling of hazardous drugs, spills, and body fl uids were discussed using, as outlined, the institution's procedure for safe handling and disposal of hazardous drugs (National Institutes of Health, Nursing and Patient Care Services, 2002) . Although the IR staff does not administer chemotherapy, potential risk of exposure to chemotherapy from body fl uids or aerosolization exists. All hospital personnel handling hazardous drugs and body fl uids post-chemotherapy infusion are responsible for following the organization's established safety measures to minimize exposure. PPE, including protective gowns, gloves, eyewear, masks, spill towels, and chemotherapy buckets for disposal of used items, was reviewed. Procedures for safe handling of chemotherapy spills and handling of body fl uids were discussed, such as wearing double gloves, the risk of splashing, quantity of the spill, and containment of the spill. Additionally, IR staff are updated annually about safe handling of hazardous spills and body fl uids post-chemotherapy infusion.
Operating Room and Nursing Staff
OR staff attend weekly one-hour educational in-service classes; during one of these classes each year, they are updated on active perfusion protocols. One of the attending surgical oncologists presents the protocols and any amendments to them during the past year. The surgeon's review is followed with nursing priorities presented by the OR oncology nurse specialist. The importance of this type of interdisciplinary staff development is to ensure that all providers understand the steps involved in the procedure and the potential endpoints. Chemotherapy will not always be deliverable regionally based on patients' anatomy. Staff need to understand this and be able to execute alternative plans laid out by the surgical oncologist. Additionally, safe handling of body fl uids and management of chemotherapy spills are reiterated.
Patient Education
The complexity and novelty of the therapies discussed in this article necessitates extensive patient education, which should be initiated when a patient is called by a research nurse to assess his or her eligibility for the procedures. The research nurse obtains an impression of a patient's ability to understand the procedures, the nature of the research, and potential side effects as well as the ability to comply with protocol.
Patient education continues when patients are evaluated in the outpatient surgical oncology clinic and continues throughout hospitalization and after discharge. Patients must sign a witnessed informed consent because the procedures are part of a clinical trial. An overview of the study and expected complications are outlined in the consent. Additionally, patient education is developed by protocol managers, interventional radiologists, and research nurses to aid patients pre-and postprocedure. For example, two procedure education booklets were developed-one describes radiofrequency ablation and the other describes the PHP procedure in the IR suite. They are available to patients on the Internet at www.cc.nih.gov/drd/rfa and www.cc.nih.gov/ccc/patient_ education/procdiag/phap.pdf, respectively. Additional education is provided on the nursing units. All materials are meant to provide comprehensive, complementary education.
Conclusion
As technology and cancer therapy continue to evolve at a rapid pace, oncology nurses must fi nd ways to care for patients in a safe and effective manner. Reference materials are not always available, so nurses must be able to apply proven and standard principles to new and unusual situations. The promise of innovative therapies impels nurses to devise creative strategies to safely implement new treatment modalities into modern nursing practice.
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